100PD - PGG β-glucan with carboplatin, paclitaxel and cetuximab for chemoimmunotherapy of advanced non-small cell lung cancer (NSCLC)

Date 28 March 2014
Event ELCC 2014
Session Poster Discussion 2
Topics Anti-Cancer Agents & Biologic Therapy
Non-Small-Cell Lung Cancer, Metastatic
Cancer Immunology and Immunotherapy
Presenter Parvis Sadjadian
Citation Journal of Thoracic Oncology (2014) 9 (Supplement 9): S7-S52. 10.1097/JTO.0000000000000131
Authors F. Schneller1, P. Sadjadian2, M. Thomas3, J. Kollmeier4, N. Bose5, M. Antonysamy5, M. Patchen6, J. Lowe6, R.D. Huhn7, P. Mattson6
  • 1Technical University Of Munich, Klinikum Rechts der Isar, 81675 - Munich/DE
  • 2Klinik Hamatoloie/onkologie, Johannes Wesling Klinikum Minden, Minden/DE
  • 3Thoraxklinik, University of Heidelberg, D-69126 - Heidelberg/DE
  • 4Lung Clinic Heckeshorn, Helios Clinic von Behring, Berlin/DE
  • 5Immunology R&d, Biothera, Inc., 55121 - Eagan/US
  • 6Clinical, Biothera, Eagan/US
  • 7Pharma Clinical Development, Biothera, Inc., 55121 - Eagan/US

Abstract

PGG β-glucan (Imprime PGG®, Imprime) primes innate immune cells to kill monoclonal antibody-targeted cancer cells via complement receptor 3 (CR3). In humans, naturally occurring anti-beta glucan antibodies (ABA) are required for binding of Imprime to CR3. Subjects with ABA levels conducive to binding are considered “biomarker positive” (BM+).